Combination Drug Delivery Approaches in Metastatic Breast Cancer

Table 3

Combination drug delivery systems based on liposomes.

Formulation	Therapeutics	Indication	Status	Targeting	References
PEG-Liposome	Topotecan + Vincristine	Brain cancer	In vivo	Passive
Polymer-caged nanobins (PCN); Liposome surrounded by cholesterol-terminated poly(acrylic acid)	Cisplatin + Doxorubicin	Various cancers	In vitro	Passive	[67]
Liposome	Cytarabine + Daunorubicin	Acute myeloid leukemia	Phase II	Passive	[71]
Liposome	Irinotecan + Floxuridine	Colorectal cancer	Phase II	Passive	[72, 73]
Mixture of two Liposomes	Irinotecan + Cisplatin	Small-cell lung cancer	In vivo	Passive	[74]
PEG-Liposome	Quercetin + Vincristine	Hormone- and TRZ-insensitive breast cancer	In vivo	Passive	[75]
Cationic, anionic PEG-Liposome	siRNA + Doxorubicin	MDR-breast cancer	In vivo	Passive	[76]
Liposome	6-Mercaptopurine + Daunorubicin	Acute myeloid leukemia	In vitro	Passive	[77]
Transferrin- (Tf-) conjugated PEG-Liposome	Doxorubicin + Verapamil	MDR-leukemia	In vitro	Active (Tf receptor)	[69]

PEG: polyethylene glycol; MDR: multidrug resistant; TRZ: trastuzumab.